Guardant Health shares (NASDAQ: GH) gave holders a sharp reminder of how quickly biotech valuations can shift when insurance decisions unlock new markets. Shares in the US-listed cancer screening company jumped after UnitedHealth Group, the nation’s largest health insurer, agreed to cover Shield, Guardant’s blood-based colorectal cancer test, as a first-line screening option for members aged 45 and older.
The Guardant Health stock price has added 34.21% over the past month of trading, to bring the cumulative 1 year gain to a mighty 237%.
The news triggered an immediate analyst upgrade as Bernstein lifted its price target on Guardant Health to US$200 from US$175, maintaining an Outperform rating. The move came less than a day after UnitedHealth’s coverage announcement, suggesting a potential upside of ~20% from here.
Guardant shares now trade close to their 52-week high on the day, with the $170 level the next target for bulls to break down.
The News Driving The Latest Leg of The Rally at GH
UnitedHealth Group announced coverage for Shield as a primary colorectal cancer screening test for millions of members aged 45 and older. This marks the first time a major US insurer has added Shield to its first-line screening menu, placing it alongside established options like colonoscopy and stool-based tests.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Bernstein analyst Eve Burstein responded by raising her price target on Guardant Health stock to US$200 from US$175, keeping an Outperform rating intact. The upgrade reflected the significance of UnitedHealth’s decision, effectively validating Shield’s commercial pathway and pulling forward revenue expectations that Wall Street hadn’t anticipated for several more years.
Insurance coverage is the gatekeeper for diagnostic tests in the US healthcare system. Without payer support, even clinically validated products struggle to achieve meaningful commercial scale. UnitedHealth’s decision effectively unlocked access to a substantial portion of the addressable screening market, years earlier than many analysts had modelled.
Colorectal cancer is the second-leading cause of cancer death in the United States, and screening rates remain below public health targets. Blood-based tests like Shield aim to improve uptake by offering a non-invasive alternative to colonoscopy, potentially reaching patients who avoid more invasive procedures.
What is Shield?
Shield is Guardant Health’s flagship cancer screening test. It uses a blood draw to detect circulating tumour DNA, aiming to identify colorectal cancer at early stages when treatment outcomes are most favourable. The test received US Food and Drug Administration approval, positioning it as a potential complement or alternative to existing screening methods.
Before UnitedHealth’s announcement, payer coverage for Shield was limited. Most insurers had not yet added blood-based colorectal cancer screening to their covered benefits, citing the need for more real-world evidence and cost-effectiveness data. This created a commercial bottleneck, as Shield was approved and available, but patient access remained constrained by out-of-pocket costs.
The broader diagnostics sector has been watching closely. Blood-based cancer screening represents a large and growing market opportunity, but commercialisation timelines have proven longer than early optimists predicted. Payer adoption remains the critical path to volume, and UnitedHealth’s decision signals that at least one major insurer now sees sufficient clinical and economic value to offer first-line coverage.
Markets will now watch for follow-on coverage decisions from other major US insurers. If additional payers adopt Shield as a first-line screening option, the revenue ramp could accelerate further. Conversely, if UnitedHealth’s decision remains an outlier, the commercial outlook may prove more gradual than the initial share price reaction suggests.
